Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00061594 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration
A Phase 3 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 3
- Development phase
- 426
- Enrollment target
NCT00061594 is a Phase 3 study that has completed, run by Genentech. The registered enrollment target is 426 participants.
The verdict
NCT00061594, a Phase 3 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 426 participants
- Enrollment target
Study Summary
This is a phase III, multicenter, randomized, double-masked, active treatment-controlled study of intravitreally administered ranibizumab compared with verteporfin (Visudyne) photodynamic therapy (PDT) in treating subfoveal neovascular mascular degeneration.
Interventions
- DRUG rhuFab V2 (ranibizumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 426 participants |
| Start Date | 2003-05 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00061594
The ClinicalTrials.gov registry entry for NCT00061594 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 426 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rhuFab V2 (ranibizumab) is the first listed.
NCT00061594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00061594 about?
NCT00061594 is a clinical study titled "A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration". This is a phase III, multicenter, randomized, double-masked, active treatment-controlled study of intravitreally administered ranibizumab compared with verteporfin (Visudyne) photodynamic therapy (PDT) in treating subfoveal neovascular mascular degeneration.
What is the current status of trial NCT00061594?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 426 participants. The study started on 2003-05. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00061594?
The interventions under investigation include: rhuFab V2 (ranibizumab) (DRUG).
Who is sponsoring clinical trial NCT00061594?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.